Alamar Biosciences, Inc.
ALMR
$29.16
-$0.79-2.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Net Income | -87.94% | -178.43% | |||
| Total Depreciation and Amortization | 23.39% | 31.42% | |||
| Total Amortization of Deferred Charges | 59.09% | 59.52% | |||
| Total Other Non-Cash Items | 660.39% | 1,439.70% | |||
| Change in Net Operating Assets | 26.92% | -61.26% | |||
| Cash from Operations | 4.71% | -55.70% | |||
| Capital Expenditure | -383.67% | -8.30% | |||
| Sale of Property, Plant, and Equipment | -- | -- | |||
| Cash Acquisitions | -- | -- | |||
| Divestitures | -- | -- | |||
| Other Investing Activities | -726.56% | -101.01% | |||
| Cash from Investing | -773.15% | -104.57% | |||
| Total Debt Issued | -- | -- | |||
| Total Debt Repaid | -- | -- | |||
| Issuance of Common Stock | 125,371.34% | 641.98% | |||
| Repurchase of Common Stock | -- | -- | |||
| Issuance of Preferred Stock | -- | -- | |||
| Repurchase of Preferred Stock | -- | -- | |||
| Total Dividends Paid | -- | -- | |||
| Other Financing Activities | -- | -- | |||
| Cash from Financing | 122,973.78% | 22,846.91% | |||
| Foreign Exchange rate Adjustments | -97.92% | -139.10% | |||
| Miscellaneous Cash Flow Adjustments | -- | -- | |||
| Net Change in Cash | 962.47% | 699.45% | |||